<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288261</url>
  </required_header>
  <id_info>
    <org_study_id>10-0884-04</org_study_id>
    <secondary_id>NCI-2011-00026</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT01288261</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Monoclonal antibodies, such as bavituximab, can block tumor growth in different ways. Some&#xD;
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill&#xD;
      them or carry tumor-killing substances to them. Giving paclitaxel together with bavituximab&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of giving paclitaxel and bavituximab&#xD;
      together in treating patients with Human Epidermal growth factor Receptor 2 (HER2 )-negative&#xD;
      metastatic breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety, feasibility, and tolerability of combining paclitaxel with weekly&#xD;
      bavituximab therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe changes in pharmacodynamic markers and coagulation markers in response to&#xD;
      single agent and combined therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive paclitaxel intravenously (IV) on days 1, 8, and 15 and bavituximab IV on&#xD;
      days 1, 8, 15, and 22 (days 15 and 22 only of course 1). Courses repeat every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of grade 3 or higher toxicities associated with the combination therapy as classified using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of the regimen by RECIST</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurable changes in levels of circulating endothelial cells (CEC), circulating endothelial progenitors (CEP), apoptotic CEC, and circulating tumor cells (CTC), as well as changes in cell-specific microparticle formation in response to therapy</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of coagulation as measured by changes in D-dimer levels and platelet activation markers in response to therapy</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection and storage of additional plasma for further analysis of angiogenic markers (i.e., VCAM and VEGF)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bavituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Tarvacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent has been obtained&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Histologically or cytologically confirmed, Her-2 negative breast cancer with evidence&#xD;
             of metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors&#xD;
             (RECIST)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status =&lt; 2&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count [ANC] &gt;= 1,500 cells/uL;&#xD;
             hemoglobin &gt;= 9 g/dL; platelets &gt;= 100,000/uL and =&lt; 500,000/uL)&#xD;
&#xD;
          -  Adequate renal function (serum creatinine =&lt; 1.5 mg/dL or calculated creatinine&#xD;
             clearance &gt;= 60 ml/min)&#xD;
&#xD;
          -  Adequate hepatic function (total or direct bilirubin =&lt; Upper Limit of Normal (ULN),&#xD;
             Alk Phos =&lt; 4 x ULN)&#xD;
&#xD;
          -  Prothrombin time international normalized ratio within institutional normal limits&#xD;
&#xD;
          -  Activated partial thromboplastin time =&lt; 1.5 x ULN&#xD;
&#xD;
          -  New York Heart Association classification I or II&#xD;
&#xD;
          -  Female patients must have a negative urine pregnancy test at prestudy (not applicable&#xD;
             to patients with bilateral oophorectomy and/or hysterectomy or to those patients who&#xD;
             are postmenopausal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease,&#xD;
             Hemophilia)&#xD;
&#xD;
          -  Any current evidence of clinically significant active bleeding&#xD;
&#xD;
          -  Any history of significant thromboembolic events (i.e., deep vein thrombosis or&#xD;
             pulmonary thromboembolism) within the last five years or requirement for ongoing&#xD;
             therapy with oral or parenteral anticoagulants; central venous catheter-related&#xD;
             thrombosis &gt; 12 months ago and low dose anticoagulants to maintain patency of lines&#xD;
             are allowed; patients taking anticoagulants (e.g., prophylactic heparin or enoxaparin)&#xD;
             are required to observe the washout period of 1 week prior to study drug infusion on&#xD;
             Study Day 1&#xD;
&#xD;
          -  Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement,&#xD;
             anti-estrogen); patients taking concurrent hormone therapy are required to observe the&#xD;
             washout period of 2 weeks prior to study drug infusion on Study Day 1&#xD;
&#xD;
          -  Grade 2 or higher peripheral neuropathy (e.g., numbness, tingling, and/or pain in&#xD;
             distal extremities)&#xD;
&#xD;
          -  More than one prior chemotherapy regimen for metastatic disease (prior adjuvant&#xD;
             chemotherapy or any number of prior hormonal therapies are allowed)&#xD;
&#xD;
          -  Chemotherapy, immunotherapy or radiotherapy within 2 weeks of Study Day 1 or not&#xD;
             having recovered from significant treatment-related side effects due to agents&#xD;
             administered previously; patients who have receive nitrosoureas and mitomycin C&#xD;
             therapy are required to observe the washout period of 6 weeks prior to study drug&#xD;
             infusion on Study Day 1&#xD;
&#xD;
          -  Allergy to polysorbate 80 or drugs containing polyoxyethylated castor oil (e.g.&#xD;
             cyclosporine)&#xD;
&#xD;
          -  Symptomatic or clinically active Central Nervous System (CNS) disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of Study Day 1&#xD;
&#xD;
          -  Female patients pregnant or nursing&#xD;
&#xD;
          -  All patients of reproductive potential must agree to use appropriate non-hormonal form&#xD;
             of contraception&#xD;
&#xD;
          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)&#xD;
&#xD;
          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,&#xD;
             or transient ischemic attack&#xD;
&#xD;
          -  A history of any condition requiring anti-platelet therapy (e.g., phosphodiesterase&#xD;
             inhibitors, adenosine diphosphate receptor antagonists) with the exception of general&#xD;
             cardiovascular prophylaxis with aspirin&#xD;
&#xD;
          -  Cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
          -  Serious non-healing wound (including wound healing by secondary intention, ulcer, or&#xD;
             bone fracture)&#xD;
&#xD;
          -  Requirement for chronic daily steroid use&#xD;
&#xD;
          -  Known chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus&#xD;
             (HBV), or Hepatitis C Virus (HCV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Stopeck</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

